抗肿瘤抗体药物的研究进展  

Advances in research on therapeutic antibodies against tumors

作　　者：陈雪静[1] 常亮[1] 高健[1] 

机构地区：[1]华北制药集团新药研究开发有限责任公司抗体药物研制国家重点实验室,河北石家庄050015

出　　处：《中国生物制品学杂志》2015年第1期84-90,共7页Chinese Journal of Biologicals

基　　金：国家高技术研究发展计划(863计划)项目(2012AA02A306)

摘　　要：经过30多年的发展,抗肿瘤抗体药物已成为癌症治疗中最成功和最重要的策略之一。本文综述了已上市的抗肿瘤抗体药物,详细介绍了临床应用较成功的药物靶点,包括CD20、表皮生长因子受体(epithelial growth factor receptor,EGFR)、表皮生长因子受体2(HER2)、血管内皮生长因子(vascular endothelial growthfactor,VEGF),并总结了抗体偶联药物及癌症免疫疗法等新兴疗法的研究进展。As one of the most successful and the most important strategies, therapeutic antibodies against tumors have been developed for more than 30 years. This paper reviews the commercial therapeutic antibodies against tumors and their targets in clinic, including cluster of differentiation 20 （CD20）, epithelial growth factor receptor （EGFR）, human epidermal growth factor receptor 2 （HER2） and vascular endothelial growth factor （VEGF）, and summarizes the advances in research on novel therapy of tumors, including antibody-drug conjugate and immunotherapy.

关 键 词：肿瘤 抗体药物 靶点 免疫治疗 

分 类 号：R979.19[医药卫生—药品]